These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 33476434)

  • 1. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
    Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
    Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
    Peñalver FJ; Márquez JA; Durán S; Giraldo P; Martín A; Montalbán C; Sancho JM; Ramírez MJ; Terol MJ; Capote FJ; Gutiérrez A; Sánchez B; López A; Salar A; Rodríguez-Caravaca G; Canales M; Caballero MD;
    Cancer Med; 2019 Nov; 8(16):6955-6966. PubMed ID: 31573746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.
    Vitolo U; Ladetto M; Boccomini C; Baldini L; De Angelis F; Tucci A; Botto B; Chiappella A; Chiarenza A; Pinto A; De Renzo A; Zaja F; Castellino C; Bari A; Alvarez De Celis I; Evangelista A; Parvis G; Gamba E; Lobetti-Bodoni C; Ciccone G; Rossi G
    J Clin Oncol; 2013 Sep; 31(27):3351-9. PubMed ID: 23960180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe).
    Lansigan F; Costa CA; Zaki BI; Yen SP; Winer ES; Ryan H; Findley D; Metzler SR; Shaw L; Toaso B; MacKenzie TA; Chen Y; Beaven AW
    Clin Cancer Res; 2019 Oct; 25(20):6073-6079. PubMed ID: 31243122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
    Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
    Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
    Cheah CY; Nastoupil LJ; McLaughlin P; Fanale MA; Neelapu SS; Fayad LE; Hagemeister FB; Fowler NH
    Br J Haematol; 2016 Nov; 175(3):531-533. PubMed ID: 26683805
    [No Abstract]   [Full Text] [Related]  

  • 7. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.
    Evens AM; Hong F; Habermann TM; Advani RH; Gascoyne RD; Witzig TE; Quon A; Ranheim EA; Ansell SM; Cheema PS; Dy PA; O'Brien TE; Winter JN; Cescon TP; Chang JE; Kahl BS
    Clin Cancer Res; 2020 Sep; 26(17):4468-4477. PubMed ID: 32532790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the
    Storti S; Spina M; Pesce EA; Salvi F; Merli M; Ruffini A; Cabras G; Chiappella A; Angelucci E; Fabbri A; Liberati AM; Tani M; Musuraca G; Molinari A; Petrilli MP; Palladino C; Ciancia R; Ferrario A; Gasbarrino C; Monaco F; Fraticelli V; De Vellis A; Merli F; Luminari S
    Haematologica; 2018 Aug; 103(8):1345-1350. PubMed ID: 29748444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consolidation with
    Miura K; Tsujimura H; Masaki Y; Iino M; Takizawa J; Maeda Y; Yamamoto K; Tamura S; Yoshida A; Yagi H; Yoshida I; Kitazume K; Masunari T; Choi I; Kakinoki Y; Suzuki R; Yoshino T; Nakamura S; Hatta Y; Yoshida T; Kanno M
    Hematol Oncol; 2021 Feb; 39(1):51-59. PubMed ID: 32978820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
    Gyan E; Sonet A; Brice P; Anglaret B; Laribi K; Fruchart C; Tilly H; Araujo C; Soubeyran P; Gonzalez H; Morineau N; Nicolas-Virelizier E; Ghesquières H; Salles B; Bouabdallah R; Orfeuvre H; Fahri J; Couturier O; Xerri L; Feugier P;
    Br J Haematol; 2018 Oct; 183(1):76-86. PubMed ID: 30117149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.
    Sakai R; Ohmachi K; Sano F; Watanabe R; Takahashi H; Takasaki H; Tanaka M; Hattori Y; Kimura H; Takimoto M; Tachibana T; Tanaka E; Ishii Y; Ishiyama Y; Hagihara M; Miyazaki K; Yamamoto K; Tomita N; Ando K
    Ann Hematol; 2019 Sep; 98(9):2131-2138. PubMed ID: 31286196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
    Rueda A; Calvo V; Casanova M; Rodriguez-Abreu D; Aguiar D; Llanos M; Alvarez R; Martinez-Banaclocha N; Alfaro J; Quero C; Blasco A; de la Cruz Merino L; Herrero J; García-Arroyo FR; Provencio M
    Leuk Lymphoma; 2019 Jun; 60(6):1576-1579. PubMed ID: 30516082
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
    Blum KA; Polley MY; Jung SH; Dockter TJ; Anderson S; Hsi ED; Wagner-Johnston N; Christian B; Atkins J; Cheson BD; Leonard JP; Bartlett NL
    Cancer; 2019 Oct; 125(19):3378-3389. PubMed ID: 31174236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
    J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
    Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
    Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
    Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P; Smith SD; Mukhija D; Jagadeesh D; Desai A; Alderuccio JP; Lossos IS; Mehra P; Portell CA; Goldman ML; Calzada O; Cohen JB; Hussain MJ; Ghosh N; Caimi P; Tiutan T; Martin P; Kodali A; Evens AM; Kahl BS
    Br J Haematol; 2019 Feb; 184(4):524-535. PubMed ID: 30575016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
    Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.
    Zohren F; Bruns I; Pechtel S; Schroeder T; Fenk R; Czibere A; Maschmeyer G; Kofahl-Krause D; Niederle N; Heil G; Losem C; Welslau M; Brugger W; Germing U; Kronenwett R; Barth J; Rummel MJ; Haas R; Kobbe G
    Blood; 2015 Sep; 126(12):1407-14. PubMed ID: 26239087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.